JPRN-UMIN000001741
Completed
未知
Phase II study of S-1 combined with irinotecan in patients with advanced colorectal cancer - Phase II study of S-1 combined with irinotecan
Showa University School of Medicin0 sites40 target enrollmentFebruary 28, 2009
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Showa University School of Medicin
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)prior chemotherapy received for advanced disease; 2\)other severe medical conditions; 3\)other active malignancies;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)Colorectal CancerJPRN-UMIN000006823Fukuoka Tumor Research(FUTURE)30
Completed
Phase 2
Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.Colorectal cancerJPRN-UMIN000006307Kyushu Study group of Clinical Cancer37
Completed
Phase 2
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Panitumumab as second line treatment in patients with KRAS wild type unresectable advanced colorectal cancer (mCRC).metastatic colorectal cancerJPRN-UMIN000009317Yamaguchi University Department of Digestive Surgery and Surgical Oncology30
Completed
Phase 2
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Bevacizumab as second line treatment in patients with KRAS mutant type unresectable advanced colorectal cancer (mCRC).metastatic colorectal cancerJPRN-UMIN000009318Yamaguchi University Department of Digestive Surgery and Surgical Oncology30
Completed
Phase 2
Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal canceradvanced/metastatic colorectal cancerJPRN-UMIN000004882PO Hokkaido Gastrointestinal Cancer Study Group (HGCSG)80